A digital portal can enhance patient engagement during and after clinical trial participation, according to a study published April 11 in JNCI Cancer Spectrum.
Led by researchers from Columbus-based Ohio State University, the study followed 2,221 patients enrolled in the National Cancer Institute-sponsored Multi-Cancer Early Detection Biobank Study and assessed the implementation of a patient engagement portal developed by the Alliance for Clinical Trials in Oncology.
Here are five things to know from the study:
- Among 2,221 trial participants, 40% chose to enroll in the patient engagement portal.
Of those, 361 and 310 completed questions on demographics and social determinants of health, respectively. - Patients receiving care at community centers were more likely to enroll in the portal than those at academic centers.
- Of all participants, 84% reported having a positive experience with the portal, 96% said the portal was easy to access and 93% said the surveys were easy to complete.
- Digital portals may facilitate future patient engagement as well, with 93% and 98% of participants agreeing to be contacted about future research and health-related follow-ups, respectively.
- “A user-centered development approach produced a feasible, well-received digital engagement platform within a national oncology network,” the study authors wrote. “High willingness to contribute data and remain reachable suggests PEP may serve as an effective model for sustained participant engagement in cancer research.”
Read the full study here.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
